# Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Source: https://onco.cc/key-papers/paper-roar-lancet-oncol-2020/  
OnCo record `paper-roar-lancet-oncol-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the ROAR trial registered as NCT02034110, in The Lancet Oncology (2020), chosen as the most cited paper whose own text cites the registry id.

## Summary

Background: Effective treatments for patients with cholangiocarcinoma after progression on gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have been found in 5% of biliary tract tumours. The combination of dabrafenib and trametinib has shown activity in several BRAF V600E -mutated cancers. We aimed to assess the activity and safety of dabrafenib and trametinib combination therapy in patients with BRAF V600E -mutated biliary tract cancer.

Methods: This study is part of an ongoing, phase 2, open-label, single-arm, multicentre, Rare Oncology Agnostic Research (ROAR) basket trial in patients with BRAF V600E -mutated rare cancers. Patients were eligible for the biliary tract cancer cohort if they were aged 18 years or older, had BRAF V600E -mutated, unresectable, metastatic, locally advanced, or recurrent biliary tract cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received previous systemic treatment. All patients were treated with oral dabrafenib 150 mg twice daily and oral trametinib 2 mg once daily until disease progression or intolerance of treatment. The primary endpoint was the overall response rate, which was determined by Response Evaluation Criteria in Solid Tumors version 1.1 in the intention-to-treat evaluable population, which comprised all enrolled patients regardless of receiving treatment who were evaluable (ie, had progression, began a new anticancer treatment, withdrew consent, died, had stable disease for 6 weeks or longer, or had two or more post-baseline assessments). The ROAR trial is registered with ClinicalTrials.gov, NCT02034110. These results are based on an interim analysis; the study is active but not recruiting.

Findings: Between March 12, 2014, and July 18, 2018, 43 patients with BRAF V600E -mutated biliary tract cancer were enrolled to the study and were evaluable. Median follow-up was 10 months (IQR 6-15). An investigator-assessed overall response was achieved by 22 (51%, 95% CI 36-67) of 43 patients. An independent reviewer-assessed overall response was achieved by 20 (47%, 95% CI 31-62) of 43 patients. The most common grade 3 or worse adverse event was increased γ-glutamyltransferase in five (12%) patients. 17 (40%) patients had serious adverse events and nine (21%) had treatment-related serious adverse events, the most frequent of which was pyrexia (eight [19%]). No treatment-related deaths were reported.

Interpretation: Dabrafenib plus trametinib combination treatment showed promising activity in patients with BRAF V600E -mutated biliary tract cancer, with a manageable safety profile. Routine testing for BRAF V600E mutations should be considered in patients with biliary tract cancer.

Funding: GlaxoSmithKline and Novartis.

Indexed on Europe PMC as PubMed record 32818466 (DOI 10.1016/s1470-2045(20)30321-1). Its abstract cites the registry id NCT02034110, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Tags: europepmc-ingest
- Journal: The Lancet Oncology
- Year: 2020
- DOI: 10.1016/s1470-2045(20)30321-1
- Authors: Subbiah V, Lassen U, Élez E, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT02034110 with the most citations, so it is the natural first reading for anyone following the ROAR trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- Lancet Oncol 2020: https://doi.org/10.1016/s1470-2045(20)30321-1
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32818466/
- Europe PMC: https://europepmc.org/article/MED/32818466
- ClinicalTrials.gov NCT02034110: https://clinicaltrials.gov/study/NCT02034110

## Connected records

- trials: [ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort](https://onco.cc/trials/roar/)
- journals: [The Lancet Oncology](https://onco.cc/journals/lancet-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-roar-lancet-oncol-2020.json